Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) announced on Thursday that it has received a EUR2.4m grant from the German Federal Ministry of Education and Research (BMBF) to support its Phase 2 clinical trial for NOX-A12, a potential treatment for glioblastoma.
This non-dilutive funding, combined with other grants totalling approximately EUR5m, will support the randomised controlled study evaluating NOX-A12 in combination with bevacizumab.
The Phase 2 trial, approved by the US Food and Drug Administration (FDA) and the German regulator, aims to optimise the dosing regimen and assess the efficacy of the combination therapy.
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Boehringer Ingelheim discontinues development of NYP2 agonist